Pharmaceutical Technology's Trends in Manufacturing eBook
Read the article:
Manufacturing OSD Forms: Key Trends Shaping the Industry
Read the eBook:
Manufacturing OSD Forms: Key Trends Shaping the Industry
News
Article
Pharmaceutical TechnologyPharmaceutical Technology, Trends in Manufacturing, May 2022
Volume 2022 eBook
Issue 2
Pages: 4–9
The latest manufacturing technologies are essential for helping pharmaceutical formulators meet up-and-coming trends in OSD treatments.
AdobeStock_133150233_Proxima Studio
Alternative dosage forms are helping the pharmaceutical industry tackle some of the biggest challenges associated with efficacy and patient adherence. For example, oral films that help administer treatments to pediatric and geriatric patients, and wearable injectors that enable the self-administering of high-volume treatments. Amid these innovations, it’s easy to overlook the humble tablets and capsules that have been used for generations and continue to be the most popular course of treatment around the world. The global capsule market is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2021 to 2030 (1). This amounts to approximately 700 billion units every year around the world, according to ACG data (2).
But capsules are more than the familiar favorite. Recent developments are taking oral solid dosage (OSD) solutions to new heights. Now more than ever, innovation is fueled by the need to differentiate and to deliver sustainable, advanced products in the crowded pharmaceutical market. Pharmaceutical manufacturers must also navigate evolving delivery formats, the economy of scale, complex regulatory landscapes, increasingly stressed supply chains, and digitalization, all while maintaining the highest quality standards. Therefore, it’s crucial to take steps to meet these growing challenges using the latest advanced manufacturing technologies.
Read this article in Pharmaceutical Technology's Trends in Manufacturing eBook.
References
1. ResearchAndMarkets, Empty Capsules Market by Product, Raw Material, Therapeutic Application and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030 (December 2021).
2. WHO, “1 in 10 Medical Products in Developing Countries is Substandard or Falsified,” (November 2017).
About the authors
Laxman Shetty is the vice president, operations; Jnanadeva Bhat is the vice president, formulation R&D (pharma and nutra); and Anita Solanki is the lead for whitepapers and publications, formulation R&D (pharma and nutra), all for ACG.
Article details
Pharmaceutical Technology
eBook: Trends in Manufacturing
May 2022
Pages: 4–9
Citation
When referring to this article, please cite it as L. Shetty, J. Bhat, and A. Solanki, "Manufacturing OSD Forms: Key Trends Shaping the Industry," Pharmaceutical Technology's Trends in Manufacturing eBook (May 2022).
Articles in this issue
Demonstrating a Fully Continuous Bioprocess
Manufacturing OSD Forms: Key Trends Shaping the Industry
Don’t Gamble on Tablet Tooling Maintenance
Implementing Continuous Bioprocessing: From Theory to Practice
The Lighthouse Effect: Using Technology to Improve Life Sciences Manufacturing
Plan Early: Optimizing Stability During Lyophilization
Opportunities for Growth and Breakthroughs for Cell and Gene Therapies
Converting Injectable Therapies to Combination Drug-Device Products
Using Robotics in the Aseptic Manufacturing Facility of the Future
Embracing New Realities
Recent Videos
Related Content
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Article
Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
